Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab

Journal of Crohn's and Colitis

Volumn 6, Issue 5, 2012, Pages 529-535

  Ogawa, Kotaro ^a   Matsumoto, Takayuki ^a   Esaki, Motohiro ^a   Torisu, Takehiro ^a   Iida, Mitsuo ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU CENTRAL HOSPITAL   (Japan)

Author keywords

Crohn's disease; Cytokine; Infliximab; Maintenance treatment

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPHENHYDRAMINE; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; PARACETAMOL; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CROHN DISEASE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84860835015     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.10.010     Document Type: Article

References (43)

1. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 1997, 337:1029-1035.
2. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
3. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. ACCENT I study group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
4. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
5. Arnott I.D., McNeill G., Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003, 17:1451-1457.
6. Vermeire S., Louis E., Carbonez A., Van Assche G., Noman M., Belaiche J., et al. Belgian group of infliximab expanded access program in Crohn's disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002, 97:2357-2363.
7. Lionetti P., Bronzini F., Salvestrini C., et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003, 18:425-431.
8. Weinberg A.M., Rattan S., Lewis J.D., Su C., Katzka D.A., Deren J., et al. Strictures and response to infliximab in Crohn's disease. Am J Gastroenterol 2002, 97:S255.
9. Matsumoto T., Iida M., Kohgo Y., Imamura A., Kusugami K., Nakano H., et al. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy. Scand J Gastroenterol 2005, 40:1423-1430.
10. Esters N., Vermeire S., Joossens S., Noman M., Louis E., Belaiche J., et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002, 97:1458-1462.
11. Louis E., El Ghoul Z., Vermeire S., Rutgeerts P., Paintaud G., Belaiche J., et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004, 19:511-519.
12. Hlavaty T., Pierik M., Henckaerts L., Ferrante M., Joossens S., van Schuerbeek N., et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005, 22:613-626.
13. Dideberg V., Théâtre E., Farnir F., Vermeire S., Rutgeerts P., De Vos M., et al. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics 2006, 16:727-734.
14. Jürgens M., Laubender R.P., Hartl F., Weidinger M., Seiderer J., Wagner J., et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010, 105:1811-1819.
15. Martinez-Borra J., Lopez-Larrea C., Gonzalez S., Fuentes D., Dieguez A., Deschamps E.M., et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002, 97:2350-2356.
16. Andus T., Herfarth F., Obermeier T., Kuehbacher T., Mascheretti S., Thriene W., et al. Prediction of response to treatment with infliximab (Remicade) in a German prospective open-label multicenter trial in refractory Crohn's disease. Gastroenterology 2001, 120:A621.
17. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009, 58:1152-1167.
18. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007, 204:1849-1861.
19. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010, 42:1118-1125.
20. Rossin E.J., Lage K., Raychaudhuri S., Xavier R.J., Tatar D., Benita Y., et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 2011, 7:e1001273.
21. Best W., Becktel J., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976, 70:439-444.
22. Myren J., Bouchier I.A., Watkinson G., Softley A., Clamp S.E., de Dombal F.T. The O.M.G.E multinational inflammatory bowel disease survey 1976-1982. A further report on 2657 cases. Scand J Gastroenterol Suppl 1984, 95:1-27.
23. Brennan F.M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989, 334:244-247.
24. Haworth C., Brennan F.M., Chantry D., Turner M., Maini R.N., Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol 1991, 21:2575-2579.
25. Lügering A., Schmidt M., Lügering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
26. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Bauer C.A, Hoedemaeker I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
27. Neurath M.F. IL-23: a master regulator in Crohn disease. Nat Med 2007, 13:26-28.
28. Seiderer J., Elben I., Diegelmann J., Glas J., Stallhofer J., Tillack C., et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008, 14:437-445.
29. Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S.T., Otte J.M., et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006, 290:G827-G838.
30. Dambacher J., Beigel F., Zitzmann K., De Toni E.N., Göke B., Diepolder H.M., et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 2009, 58:1207-1217.
31. Komatsu M., Kobayashi D., Saito K., Furuya D., Yagihashi A., Araake H., et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001, 47:1297-1301.
32. Gustot T., Lemmers A., Louis E., Nicaise C., Quertinmont E., Belaiche J., et al. Profiles of soluble cytokine receptors in Crohn's disease. Gut 2005, 54:488-495.
33. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
34. Schmidt C., Giese T., Ludwig B., Mueller-Molaian I., Marth T., Zeuzem S., et al. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 2005, 11:16-23.
35. Fuss I.J., Becker C., Yang Z., Groden C., Hornung R.L., Heller F., et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006, 12:9-15.
36. Liu Z., Yadav P.K., Xu X., Su J., Chen C., Tang M., et al. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. J Leukoc Biol 2011, 89:597-606.
37. Nancey S., Hamzaoui N., Moussata D., Graber I., Bienvenu J., Flourie B. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci 2008, 53:242-247.
38. Charles P., Elliott M.J., Davis D., Potter A., Kalden J.R., Antoni C., et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999, 163:1521-1528.
39. Levälampi T., Honkanen V., Lahdennne P., Nieminen R., Hakala M., Moilanen E. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2007, 36:189-193.
40. Schmechel S., Konrad A., Diegelmann J., Glas J., Wetzke M., Paschos E., et al. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis 2008, 14:204-212.
41. Glas J., Stallhofer J., Ripke S., Wetzke M., Pfennig S., Klein W., et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am J Gastroenterol 2009, 104:1737-1744.
42. Afif W., Loftus E.V., Faubion W.A., Kane S.V., Bruining D.H., Hanson K.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
43. Chamberlain P., Mire-Sluis A.R. An overview of scientific and regulatory issues for the immunogenicity of biological products. Dev Biol (Basel) 2003, 112:3-11.